Impact of artificial intelligence arrhythmia mapping on time to first ablation, procedure duration, and fluoroscopy use

<bold>Introduction: </bold>Artificial intelligence (AI) ECG arrhythmia mapping provides arrhythmia source localization using 12-lead ECG data; whether this information impacts procedural efficiency is unknown. We performed a retrospective, case-control study to evaluate the hypothesis that AI ECG mapping may reduce time to ablation, procedural duration, and fluoroscopy. <bold>Materials and methods: </bold>Cases in which system output was used were retrospectively enrolled according to IRB-approved protocols at each site. Matched control cases were enrolled in reverse chronological order beginning on the last day for which the technology was unavailable. Controls were matched based upon physician, institution, arrhythmia, and a predetermined complexity rating. Procedural metrics, fluoroscopy data, and clinical outcomes were assessed from time-stamped medical records. <bold>Results: </bold>The study group consisted of 28 patients (age 65 +/- 11 years, 46% female, left atrial dimension 4.1 +/- 0.9 cm, LVEF 50 +/- 18%) and was similar to 28 controls. The most common arrhythmia types were atrial fibrillation (n = 10), premature ventricular complexes (n = 8), and ventricular tachycardia (n = 6). Use of the system was associated with a 19.0% reduction in time to ablation (133 +/- 48 vs. 165 +/- 49 min, p = 0.02), a 22.6% reduction in procedure duration (233 +/- 51 vs. 301 +/- 83 min, p < 0.001), and a 43.7% reduction in fluoroscopy (18.7 +/- 13.3 vs. 33.2 +/- 18.0 min, p < 0.001) versus controls. At 6 months follow-up, arrhythmia-free survival was 73.5% in the study group and 63.3% in the control group (p = 0.56). <bold>Conclusion: </bold>Use of forward-solution AI ECG mapping is associated with reductions in time to first ablation, procedure duration, and fluoroscopy without an adverse impact on procedure outcomes or complications.